Survodutide (BI 456906) is supplied by Onyx Peptides as a high-purity research material for laboratory use, with tracked, discreet UK dispatch.
What is Survodutide?
Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim with Zealand Pharma.
How Survodutide is studied
It is being studied in Phase 3 clinical research (the SYNCHRONIZE programme) and in research on fatty liver disease.
- Glucagon and GLP-1 receptor pharmacology
- Liver fat research
Survodutide from Onyx Peptides
We supply survodutide in 10 mg vials. Every batch is independently tested by HPLC to ≥99% purity before it is listed, and carries a batch number that links to its certificate of analysis.
Storage and delivery
Supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. Store the sealed vial frozen (below −18 °C) and away from light.
Orders are dispatched from the UK by tracked delivery in plain, discreet black padded packaging, with no product names on the outside. See shipping & delivery.
Frequently asked questions
What is Survodutide?
Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim with Zealand Pharma..
Is Survodutide a licensed medicine in the UK?
Survodutide is not a licensed medicine in the UK. Onyx Peptides supplies it only as a research material for in-vitro laboratory use.
How is Survodutide supplied?
Supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. Store the sealed vial frozen (below −18 °C) and away from light. Each batch is HPLC-tested to at least 99% purity.
How is my order packaged?
In plain, discreet black padded packaging with no product names on the outside, sent by tracked UK delivery.
